Sun Pharma's Phase IV Study on Dual Release Pantoprazole for GERD Gets CDSCO Panel Acceptance

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-12 08:16 GMT | Update On 2025-08-12 08:16 GMT

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the results of Sun Pharma's Phase IV clinical trial on Dual Release Gastro-Resistant Pantoprazole 80mg for the treatment of partial or non-responders to standard proton pump inhibitor (PPI) doses in gastroesophageal reflux disease (GERD). The panel noted that the findings will not be used for regulatory approvals.

The trial, titled “Dual Release Gastro-Resistant Pantoprazole 80mg for Treatment of Partial or Non-Responders to Standard Dose of Proton Pump Inhibitor (PPI) in Gastroesophageal Reflux Disease (GERD) – A Prospective pH-Metry/Impedance Controlled Study”, was reviewed at the SEC (Gastroenterology & Hepatology) meeting held on 24 July 2025.

Sun Pharma informed the committee that the study was conducted solely to generate additional data and information, not for regulatory submissions.

Pantoprazole, a proton pump inhibitor, works by binding irreversibly and specifically to the proton pump, reducing gastric acid secretion. It is used to treat erosive esophagitis and other conditions involving excess stomach acid, including GERD.

After detailed deliberation, the SEC recommended: “To accept the result of the Phase IV CT study and same may not be used for regulatory approvals.”

Also Read: Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma's Phase IV Study on Dual Release Pantoprazole for GERD Gets CDSCO Panel Acceptance

Similar News

Torrent Pharma Receives SEC Approval to Market Alogliptin-Metformin FDC, Asked to Conduct Phase IV Trial

CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens

Unique Pharma Asked To Revise BE Study Protocol for Cilnidipine-Metoprolol FDC

Beta Drugs' Methotrexate Oral Solution Gets SEC Manufacturing, Marketing Nod

Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths

CDSCO Panel Clears Eli Lilly's Tirzepatide for Phase IV Clinical Trial in India

CDSCO Panel Rejects Pure and Cure's Empagliflozin-Based FDC, Flags Risk of UTI, Genital Mycosis

Dr. Reddy's Labs Gets CDSCO Panel Nod to Manufacture, Market Semaglutide Injection